Evaxion Biotech Stock (NASDAQ:EVAX), Trade Ideas

Evaxion Biotech

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ALGM

ASST

BFRG

BOOT

BRTX

CACC

CELU

CHRW

CMAX

CMND

CMPR

CTVA

DGII

EGHT

ELAB

ELWS

ETSY

EVAX

EVER

FBLG

FCEL

HSAI

IFBD

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

MINM

NRBO

NVIV

NYCB

OGEN

PLUG

PSNY

PTON

RACE

REVB

RKLB

SPWR

SRDX

TCRT

VLCN

WOLF

YOSH

ZION

Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.

Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

AMSC

CONNEXA SPORTS TECH INC by Connexa Sports Technologies Inc.

CNXA

DCGO

ENSC

EVTV

EXTR

GNPX

GOOG

GOOGL

ALPS ETF Trusthen & Steers Global Realty Majors ETF

HTLF

KUKE

MARK

MKTX

NVVE

NYXH

OBLG

PARA

POWL

RVSN

SLDB

SNPX

TRIB

TSVT

VXRT

ZJYL

Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results.

AMD reported fourth-quarter non-GAAP earnings per share of 77 cents per share on revenue of $6.17 billion.

AMD shares dipped 3.8% to $165.49 on Wednesday.

Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Earnings

Eurozone

Commodities

Global

ANVS

GETR

KURA

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Wednesday.

The Dow traded down 0.05% to 37,886.62 while the NASDAQ rose 0.59% to 15,517.32. The S&amp;P 500 also rose, gaining, 0.29% to 4,878.52.

Dow Edges Lower; US Composite PMI Rises In January

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech AS

Danfoss Has Chosen HPE GreenLake For SAP S/4HANA Cloud Within The RISE With SAP Program And Deployed In Danfoss Data Centers To Accelerate The Company's Sustainable Cloud Journey

Macro Economic Events

Econ #s

Economics

Germany Ifo Business Climate Index For April 89.4 Vs. 88.9 Est.; 87.9 (Revised) Prior

Germany Current Assessment For April 88.9 Vs. 88.7 Est.; 88.1 Prior

Germany Business Expectations For April 89.9 Vs. 88.9 Est.; 87.7 (Revised) Prior

ALVO

Alvotech Announced Positive Topline Results From A Confirmatory Clinical Study For AVT05, Alvotech's Proposed Biosimilar To Simponi And Simponi Aria (golimumab)

In the latest development, Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) has reportedly projected a slower increase in the production and delivery of its 787 widebody jets. This is primarily due to supplier shortages,
What Happened: Scott Stocker, the 787 vice president and general manager, disclosed the situation to employees at the South Carolina facility via a memo on Monday, Reuters reported. Despite the hurdles, Boeing is determined to incrementally increase its rate to cater to the &#8220;strong demand&#8221;.
The memo highlighted, &#8220;We continue to manage through supplier shortages on a few key parts.&#8221; 
It also mentioned that customers have been notified about the anticipated slower increase in production and deliveries.
The Federal Aviation Administration (FAA) is keeping a close watch on Boeing&#8217;s challenges in procuring certain parts and is in constant communication with the company. The agency&#8217;s primary concern is to ensure that only safe and compliant airplanes are dispatched from the factory.
See Also: <a href="https://www.benzinga.com/news/24/04/38347033/bound-by-courtroom-rules-donald-trump-is-doing-something-uncommon-for-his-public-persona-staying-sil?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bound By Courtroom Rules, Donald Trump Is Doing Something Uncommon For His Public Persona: Staying Silent</a>
Boeing, scheduled to announce earnings on Wednesday, is facing scrutiny over the manufacturing of its 777 and 787 widebody jets. This comes in the wake of allegations by company engineer Sam Salehpour at a U.S. Senate hearing last week, who pointed out inadequate shimming in some areas of the 787 Dreamliner.
Furthermore, the company&#8217;s separate production of its 737 MAX single-aisle jet in Washington state has experienced a significant decline, as U.S. regulators tighten factory inspections and workers slow down the assembly line to complete outstanding work.
A Boeing spokesperson confirmed to <a href="https://pro.benzinga.com">Benzinga</a> about the memo but refrained from divulging further details.
Why It Matters: The latest development comes on the heels of <a href="https://www.benzinga.com/markets/equities/24/04/38330613/boeing-grapples-with-32-whistleblower-complaints-in-3-years-amid-mounting-safety-concerns-report">32 whistleblower complaints</a> against Boeing over the past three years, with allegations of employer retaliation being investigated by the U.S. workplace safety regulator. This has raised significant safety concerns for the company.
Moreover, as Boeing<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38365885/boeing-will-deliver-q1-earnings-while-at-center-of-air-safety-scandal-everybody-wan"> prepares to release its Q1 earnings</a>, investors are keen to see if the company&#8217;s performance can offset the recent scandals that have tarnished its public image.
Price Action: On Monday, the stock closed at 170.48, with a slight increase of 0.22% from the previous close.
Read Next: <a href="https://www.benzinga.com/markets/equities/24/04/38346938/trump-is-a-force-of-nature-reince-priebus-has-raised-70m-for-gop-convention-despite-being-pushed?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Trump Is A Force of Nature&#8217;: Reince Priebus Has Raised $70M For GOP Convention Despite Being Pushed Out</a>
Photo via Shutterstock
Editor's note: This story has been updated with a comment from Boeing on the aforementioned memo
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Equities

General

Boeing Foresees Slower 787 Production Ramp-Up Due To Supplier Shortages: Report (UPDATED)

Elon Musk, the CEO of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), has expressed his dissatisfaction with the term GPU while announcing that the company&#8217;s core AI infrastructure is no <a href="https://www.benzinga.com/news/23/08/34128510/elon-musk-affirms-training-compute-will-not-be-a-constraint-for-teslas-full-self-driving-improvement">longer training-constrained</a>.
What Happened: During the <a href="https://www.benzinga.com/news/earnings/24/04/38390883/tesla-q1-earnings-highlights-ev-giant-misses-wall-street-estimates-makes-cost-cuts-invests-in-ai-sp">first-quarter earnings call</a> on Tuesday, Musk revealed that Tesla has been actively expanding its core AI infrastructure. He stated, &#8220;We are, at this point, no longer training-constrained, and so we&#8217;re making rapid progress.&#8221;
The tech billionaire also disclosed that Tesla has installed and <a href="https://www.benzinga.com/news/24/04/38111017/tesla-ceo-elon-musk-disagrees-with-nvidias-jensen-huang-that-anyone-can-make-their-own-neural-networ">commissioned 35,000 H100</a> computers or GPUs and Tesla anticipates this number to potentially reach around 85,000 by the end of the year, primarily <a href="https://www.benzinga.com/markets/equities/24/01/36707594/not-clear-quips-elon-musk-as-tesla-enthusiast-questions-metas-plan-to-buy-nvidias-ai-chips-equiv">for training purposes</a>. 
See Also: <a href="https://www.benzinga.com/news/24/04/38395385/elon-musk-says-tesla-optimus-humanoid-robot-might-be-available-externally-by-the-end-of-next-year-he">Elon Musk Says Tesla Optimus Humanoid Robot Might Be Available Externally By The End Of Next Year: Here&#8217;s The Progress Report</a>
&#8220;We are making sure that we&#8217;re being as efficient as possible in our training,&#8221; Musk said, adding that it is not just about the number of H100s but &#8220;how efficiently they&#8217;re used.&#8221; 
During the conversation, Musk also expressed his discomfort with the term GPU. &#8220;I always feel like a wince when I say GPU because it&#8217;s not. GPU stand — G stands for graphics, and it doesn&#8217;t do graphics,&#8221; the tech mogul stated. 
&#8220;GPU is [the] wrong word,&#8221; he said, adding, &#8220;They need a new word.&#8221;
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Why It Matters: Musk&#8217;s statement came after Tesla reported its first-quarter financial revenue of $21.0 billion, which showed a 9% year-over-year decrease, missing the Street consensus estimate of $22.15 billion. The company stated that its revenue was affected by reduced average selling prices and decreased vehicle deliveries during the quarter.
On the other hand, Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) last year made a significant impact on the AI and computing sectors by introducing its H100 data center chip, which added more than $1 trillion to the company&#8217;s overall value. 
In February, earlier this year, it was reported that the demand for the H100 chip, which is four times faster than its predecessor, the A100, in training large language models or LLMs and 30 times faster in responding to user prompts, has been so substantial that customers are <a href="https://www.benzinga.com/government/24/02/37283133/nvidias-h100-chip-sparks-ai-revolution-boosting-value-by-1t-as-it-unveils-new-chips-for-china">encountering wait times of up to six months</a>.
Meanwhile, earlier this month, Piper Sandler&nbsp;analyst <a href="https://www.benzinga.com/news/24/04/38257652/nvidias-hopper-demand-and-blackwell-launch-position-makes-it-a-top-large-cap-pick-analysts">Harsh V. Kumar</a> engaged directly with Nvidia's management team and reported that despite Nvidia&#8217;s Hopper GPU being on the market for almost two years, demand remains strong, outstripping supply. <a href="https://www.benzinga.com/news/24/04/38257652/nvidias-hopper-demand-and-blackwell-launch-position-makes-it-a-top-large-cap-pick-analysts">Customers are hesitant to shift their orders</a> from the Hopper to the Blackwell, fearing extended wait times due to anticipated supply limitations.
Check out more of Benzinga&#8217;s Future Of Consumer Tech by <a href="https://www.benzinga.com/topic/consumer-tech">following this link.</a>
Read Next: <a href="https://www.benzinga.com/general/gaming/24/04/38395097/elon-musk-likes-games-originating-from-this-country-because-because-they-havet-been-corrupted-by-w">Elon Musk Likes Games Originating From This Country Because They Haven&#8217;t Been Corrupted By &#8216;Woke DEI Lies&#8217;</a>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo via Shutterstock

Tech

NVDA

TSLA

Tesla CEO Elon Musk Says He Feels 'Like A Wince' When Saying 'GPU' As He Boasts Rapid Progress With AI Compute: 'Need A New Word'

Calliditas Therapeutics AB&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALT#NASDAQ">CALT</a>), (NASDAQ&nbsp;STOCKHOLM: CALTX)&nbsp;(&quot;Calliditas&quot;) today announced that the global open-label extension (OLE) study to the Phase 3 NefIgArd study showed a treatment response consistent with the NefIgArd study across endpoints of urine protein to creatinine ration (UPCR) and estimated glomerular filtration rate (eGFR) at 9 months across all IgAN patients, including those who had previously received Nefecon in the NefIgArd study.

CALT

Calliditas Announces NefIgArd Open Label Extension Results

Evotec Fiscal 2023 Revenue $848.644M Up From $816.11M YoY, Adjusted EBITDA $$.06M

&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4148234-1&amp;h=2946051148&amp;u=https%3A%2F%2Fclarivate.com%2F&amp;a=Clarivate+Plc" target="_blank">Clarivate Plc</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLVT#NYSE">CLVT</a>), a leading global provider of transformative intelligence, today announces it has signed the&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4148234-1&amp;h=1345612360&amp;u=https%3A%2F%2Fwww.un.org%2Fsustainabledevelopment%2Fsdg-publishers-compact%2F&amp;a=United+Nations+Sustainable+Development+Goals+(UN+SDGs)+Publishers+Compact." target="_blank">United Nations Sustainable Development Goals (UN SDGs) Publishers Compact.</a>&nbsp;Signatories of the compact pledge to develop sustainable practices and act as champions of the SDGs during the&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4148234-1&amp;h=3871956681&amp;u=https%3A%2F%2Fwww.un.org%2Fsustainabledevelopment%2Fdecade-of-action%2F&amp;a=Decade+of+Action" target="_blank">Decade of Action</a>&nbsp;(2020-2030).

Government

Regulations

CLVT

Clarivate joins United Nations Sustainable Development Goals (UN SDGs) Publishers Compact

Suzano Ventures, the corporate venture capital arm of Suzano, the world&#39;s largest market pulp producer, has made a strategic investment into the Canadian materials science startup, Bioform Technologies. The investment provides up to US$5 million towards the company&#39;s seed round, enabling it to accelerate the development of its novel bio-based plastic alternatives. The products can be manufactured through modified industrial processes already used in the pulp and paper sector.
Bioform&#39;s proprietary technology rapidly produces wood pulp-reinforced hydrogels to create high-performance plastic alternatives, which can be made using Suzano&#39;s wood pulp fibre as a key input. Bioform&#39;s materials have the potential to be home compostable or recycled through existing paper recycling processes and do not require fossil-based inputs. The technology is highly versatile and has a number of applications where it could replace conventional single-use plastics, including paper recyclable thermoformable films for packaging applications and compostable heat-sealable films for pouches, agriculture, and garbage bags.
With the potential to offer an&nbsp;80 percent&nbsp;lower carbon footprint than conventional single-use plastics, Bioform&#39;s technology has similar or enhanced product performance to conventional plastics in areas such as tensile strength and permeability for oxygen or water vapor.

Suzano Ventures Invests Up To $5M Into Bioform Technologies To Further Develop Bio-based Plastic Alternatives

First&nbsp;non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in&nbsp;Europe
Conditional marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial

TVTX

CSL Vifor And Travere Therapeutics Granted European Commission Conditional Marketing Authorization For FILSPARI (Sparsentan) For The Treatment Of IgA Nephropathy

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) senior executive Lars Moravy on Tuesday clarified that the company is not inhibited by 4680 cell production to ramp Cybertrucks. 
What Happened: As compared to the previous quarter, 4680 cell production in the first quarter rose by about 18% to 20%, Moravy said during Tesla&#8217;s first-quarter earnings call. In March, the company produced enough cells <a href="https://www.benzinga.com/news/24/03/37863738/tesla-smashes-doubts-about-4680-cell-production-says-its-made-enough-batteries-for-1-000-cybertrucks">for over 1000 Cybertrucks</a> at Giga Texas in a week. 
&#8220;We expect to stay ahead of the Cybertruck ramp with the cell production throughout Q2,&#8221; Moravy said while adding that the company is looking to maintain multiple weeks of cell inventory to make sure it&#8217;s ahead of Cybertruck&#8217;s production ramp. However, the cell production will be in tandem with Cybertruck production, he noted
&#8220;We&#8217;re not going to just randomly build 4680s unless we have a place to put them and so we&#8217;re going to make sure we&#8217;re prudent about that,&#8221; he added. Moravy is Vice President of Vehicle Engineering at Tesla. 
Just a couple of weeks ago, the company made 1000 Cybertrucks in a week, Moravy said. While the company is looking to achieve volume production to bring down costs, it still faces challenges with the many new technologies and supplier limitations, he added. 
Why It Matters: In December,&nbsp;Reuters&nbsp;<a href="https://www.benzinga.com/markets/equities/23/12/36341487/teslas-cybertruck-reportedly-struggles-with-its-pioneering-4680-battery-is-250-000-production-go" target="_blank" rel="noreferrer noopener">reported</a>&nbsp;that the EV giant is struggling to make 4680 cells fast enough to meet its targeted annual delivery rate of a quarter million Cybertrucks. Tesla&#8217;s gigafactory in Texas is making only enough cells for about 24,000 Cybertrucks a year, the report said.
The annual delivery target of 250,000 Cybertrucks, company CEO Elon Musk has previously said, would not be reached this year but only<a href="https://www.benzinga.com/news/23/10/35322048/tesla-ceo-elon-musk-details-enormous-challenges-in-reaching-volume-production-for-cybertruck-we-dug" target="_blank" rel="noreferrer noopener"> in 2025.</a>
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="http://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More: <a href="https://www.benzinga.com/news/24/04/38395808/teslas-high-profile-departures-continue-as-investor-relations-head-martin-viecha-bids-farewell-after">Tesla&#8217;s High-Profile Departures Continue As Investor Relations Head Martin Viecha Bids Farewell After 7-Year Run</a>
Photo via Shutterstock

Guidance

Tesla Exec Says 1,000 Cybertrucks A Week Prove 4680 Cell Production Isn't A Bottleneck: 'We Expect To Stay Ahead...'

Under the agreement, ANGLE will develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response. Assay development will take place in ANGLE&#39;s laboratories in Guildford, UK, and follows the Company&#39;s development and launch of two highly sensitive and specific DDR assays in 2023. The 6-month development phase is worth an initial &pound;150,000 to ANGLE.

ANPCF

Angle Inks New Commercial Agreement With AstraZeneca to Enhance DNA Damage Response Detection

Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) is set to release earnings results for its first quarter after the<a href="https://www.benzinga.com/quote/META/earnings"> closing bell on April 24, 2024.</a>
Analysts expect the Menlo Park, California-based company to report quarterly earnings at $4.32 per share, up from $2.20 per share in the year-ago period. Meta is projected to report quarterly revenue of $36.16 billion, up from $28.64 billion in the year-earlier quarter, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Meta recently announced that its AI assistant, powered by the newly launched Llama 3 model, will now incorporate real-time search results from Alphabet Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google and Microsoft Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Bing.
Meta shares rose 3% to close at $496.10 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/META/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Bernstein analyst Mark Shmulik maintained an Outperform rating and raised the price target from $535 to $590 on April 18, 2024. This analyst has an accuracy rate of 82%.</li>
<li>Truist Securities analyst Youssef Squali maintained a Buy rating and boosted the price target from $525 to $550 on April 17, 2024. This analyst has an accuracy rate of 81%.</li>
<li>UBS analyst Lloyd Walmsley maintained a Buy rating and raised the price target from $530 to $610 on April 16, 2024. This analyst has an accuracy rate of 85%.</li>
<li>Stifel analyst Mark Kelley maintained a Buy rating and boosted the price target from $527 to $588 on April 16, 2024. This analyst has an accuracy rate of 87%.</li>
<li>Citigroup analyst Ronald Josey maintained a Buy rating and increased the price target from $525 to $590 on April 15, 2024. This analyst has an accuracy rate of 72%.</li>
</ul>
Read This Next: <a href="https://www.benzinga.com/news/24/04/38376630/amazon-com-united-airlines-and-2-other-stocks-insiders-are-selling">Amazon.com, United Airlines And 2 Other Stocks Insiders Are Selling</a>

Price Target

MSFT

Meta Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Timberland Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBK#NASDAQ">TSBK</a>) reported quarterly earnings of $0.70 per share. This is a 12.5 percent decrease over earnings of $0.80 per share from the same period last year. The company reported $18.25 million in sales this quarter. This is a 7.77 percent decrease over sales of $19.79 million the same period last year.

TSBK

Timberland Bancorp Q2 EPS $0.70 Down From $0.80 YoY, Sales $18.25M Down From $19.79M YoY

LPTV

Reported Earlier, NYSE American Issues Non-Compliance Warning To Loop Media For Continued Listing Standards

Management

Reported Earlier, Visionary Holdings Appoints Zhong Chen As CEO, Effective Immediately

Amid fluctuating market conditions and rumors about Elon Musk's role as the CEO of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), the tech billionaire has suggested that he <a href="https://www.benzinga.com/news/24/04/38288360/breaking-tesla-shareholders-to-vote-again-on-ceo-elon-musks-voided-47b-pay-package">continues to spend</a> the majority of his time at the EV giant. 
What Happened: On Tuesday, during <a href="https://www.benzinga.com/news/earnings/24/04/38390883/tesla-q1-earnings-highlights-ev-giant-misses-wall-street-estimates-makes-cost-cuts-invests-in-ai-sp">Tesla's first-quarter earnings call</a>, Musk was asked that considering he is leading several important companies including SpaceX and X, formerly Twitter, where does his heart actually belong.&nbsp;
The question came from Tony Sacconaghi, a Wall Street analyst from Bernstein, who asked him about the possibility of reduced involvement with Tesla at &#8220;any point over the next three years.&#8221;&nbsp;
In response, Musk sidestepped answering the question directly. He said that Tesla &#8220;constitutes a majority of my work time, and I work pretty much every day of the week, it&#8217;s rare for me to take a Sunday afternoon off.&#8221;
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
The entrepreneur went on to assert that he will make sure &#8220;Tesla is quite prosperous. And it is — like it is prosperous, and it will be very much so in the future.&#8221;
Last year, Tesla director James Murdoch created a stir when he reportedly suggested that <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/11/29760366/is-elon-musk-stepping-down-as-tesla-ceo-soon-analysts-react-to-succession-comments">Musk has identified a potential successor</a> to replace him.&nbsp;
Why It's Important: Earlier this month, Tesla's stock faced a significant downturn following a report on <a href="https://www.benzinga.com/markets/equities/24/04/38047077/tesla-stock-dives-as-q1-deliveries-disappoint-but-ev-giant-reclaims-top-spot-from-chinese-rival">disappointing first-quarter deliveries</a>. At the time, Wedbush analyst Dan Ives said that <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38202377/elon-musk-should-pledge-3-5-year-tenure-as-ceo-says-wedbushs-dan-ives-70-of-the-val">70% of Tesla's value is Musk</a>.&nbsp;
&#8220;Musk is Tesla, Tesla is Musk,&#8221; he said.
In January earlier this year, Musk said that he <a href="https://www.benzinga.com/news/24/01/36634396/elon-musk-seeks-greater-control-over-tesla-as-ai-endeavors-multiply-enough-to-be-influential-not-so">would require increased control of Tesla</a> if he is to advance AI endeavors at the company. &#8220;I am uncomfortable growing Tesla to be a leader in AI &amp; robotics without having ~25% voting control. Enough to be influential, but not so much that I can&#8217;t be overturned.&#8221;
Previously, in 2020, <a href="https://www.benzinga.com/general/24/01/36574844/elon-musk-says-he-never-wanted-to-be-ceo-of-tesla-or-anything-running-companies-hurts-my-heart-but-h">Musk admitted that he never wanted</a> to be CEO of Tesla. &#8220;This is misinterpreted like I somehow don't love Tesla, which I do, it's just like trying not to go insane with work,&#8221; he said at the time.&nbsp;&nbsp;
Check out more of Benzinga's Future Of Consumer Tech by <a href="https://www.benzinga.com/topic/consumer-tech">following this link.</a>
Read Next: <a href="https://www.benzinga.com/news/24/04/38394597/elon-musk-reacts-to-marjorie-taylor-greenes-ally-revelation-of-fine-threat-by-house-authorities-mike">Elon Musk Reacts To Marjorie Taylor Greene&#8217;s Ally Revelation Of Fine Threat By House Authorities: Mike Johnson Removing Traces Of &#8216;Betrayal of America&#8217;</a>

Elon Musk Answers Question On Reducing Involvement At Tesla In Coming 3 Years: 'It's Rare For Me To Take A Sunday Afternoon'

<ul>
<li>TANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the European Union (EU)</li>
<li>XTANDI can be given alone or in combination with androgen deprivation therapy</li>
<li>Approval is based on results from the positive Phase 3 EMBARK study which showed XTANDI alone or in combination with leuprolide reduced the risk of metastasis or death</li>
</ul>

ALPMY

Reported Earlier, Astellas' XTANDI (Enzalutamide) Granted European Commission Approval For Use In Additional Recurrent Early Prostate Cancer Treatment Setting

Evaxion Biotech A/S Adr (EVAX) has released an update. Evaxion Biotech A/S has launched a precision vaccine initiative using AI to identify new can...

Evaxion Biotech Advances AI-Driven Vaccine Development

Evaxion Biotech ADS GAAP EPS of -$0.81

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Evaxion Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/evax-stock-quote/">EVAX</a>) just reported results for the fourth quarter of 2023.<ul><li>Evaxion Biotech reported earnings per share of -$1.60. This met the analyst estimate for EPS of -$1.60.</li><li>The company reported revenue of $73,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/evax-stock-earnings-evaxion-biotech-for-q4-of-2023/">EVAX Stock Earnings: Evaxion Biotech Meets EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

EVAX Stock Earnings: Evaxion Biotech Meets EPS for Q4 2023

Evaxion Biotech A/S Adr (EVAX) has released an update. Evaxion Biotech A/S has announced its annual general meeting scheduled for April 16, 2024, e...

Evaxion Biotech Announces Upcoming Annual Meeting

Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration

Evaxion Biotech A/S Adr (EVAX) has released an update. Evaxion Biotech A/S has announced successful animal studies for their EVX-B1 vaccine candida...

Evaxion's Promising Vaccine Candidate Battles Superbug

Evaxion Biotech A/S (EVAX) Q4 2023 Earnings Call Transcript

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Evaxion Biotech (EVAX – Research Report), 60 Degrees Pharmaceutic...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Evaxion Biotech (EVAX), 60 Degrees Pharmaceuticals, Inc. (SXTP) and Genprex (GNPX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Evaxion Biotech (EVAX – Research Report), Genprex ...

Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Genprex (GNPX) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

Evaxion Biotech A/S Adr (EVAX) has released an update. Evaxion Biotech A/S has reached a significant milestone in its Phase 2 clinical trial, with ...

Evaxion Biotech Advances Personalized Cancer Vaccine

SXTP

Opinion

Press Releases

Thinking about buying stock in Kura Oncology, Akebia Therapeutics, American Airlines, Evaxion Biotech, or Minim?

IPOs

Evaxion Biotech Announces Pricing of $15 Million Public Offering

Evaxion Announces Closing of $15 Million Public Offering

Financing

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

Health Care

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

Evaxion Announces Business Update and Full Year 2023 Financial Results

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01